TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
Previous Symbol
CUSIPN/A
Phone+1-919-7658400
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares216,120,000
Market Cap$0.00
OptionableOptionable
TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its quarterly earnings results on Thursday, November, 8th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.01. The medical instruments supplier earned $5.40 million during the quarter, compared to the consensus estimate of $5.40 million. TransEnterix's quarterly revenue was up 2850.8% compared to the same quarter last year. View TransEnterix's Earnings History.
When is TransEnterix's next earnings date?
What price target have analysts set for TRXC?
3 analysts have issued 1-year price targets for TransEnterix's stock. Their forecasts range from $5.00 to $5.50. On average, they anticipate TransEnterix's stock price to reach $5.25 in the next year. This suggests a possible upside of 81.0% from the stock's current price. View Analyst Price Targets for TransEnterix.
What is the consensus analysts' recommendation for TransEnterix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransEnterix.
What are Wall Street analysts saying about TransEnterix stock?
Here are some recent quotes from research analysts about TransEnterix stock:
- 1. According to Zacks Investment Research, "TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States. " (11/17/2018)
- 2. BTIG Research analysts commented, "with TransEnterix announced the acquisition of MST Israeli company that has created an image analytics technology that uses artificial intelligence, scene recognition, and machine learning. With the cash + stock transaction (worth ~$33M as of 9/21 closing price) expected to close in Q4, TRXC will pick up the IP portfolio (30 patents, 31 pending), technology assets, and MST’s employees. Though the co’s AutoLap platform has FDA 510(k) and CE Mark clearance, TRXC does not intend to sell it as a standalone product. Instead, its capabilities— including dynamic 3D digital measurement, auto zoom, and anatomical structure identification—will be integrated into Senhance. Timing for these enhancements is unclear, though it is likely to take quarters, not years. We see this as an exciting step toward advanced digital laparoscopy, but our near-term focus remains on system sales." (9/25/2018)
Has TransEnterix been receiving favorable news coverage?
News headlines about TRXC stock have trended somewhat positive this week, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TransEnterix earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
Are investors shorting TransEnterix?
TransEnterix saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 38,415,394 shares, an increase of 0.6% from the November 15th total of 38,200,890 shares. Based on an average daily volume of 3,214,929 shares, the short-interest ratio is presently 11.9 days. Currently, 21.6% of the company's stock are short sold. View TransEnterix's Current Options Chain.
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include Advanced Medical Solutions (AMS), Akers Biosciences (AKR), Ansell (ANN), Bovie Medical (BVX), Bovie Medical (BVX), Clover (CLV), CONVATEC GRP PL/ADR (CNVVY), CRH Medical (CRHM), CRH Medical (CRH), Daxor (DXR), Enerplus (ERF), Essilor International Cmgn Gnl D Optq (EI), Gerresheimer (GXI), InfuSystem (INFU) and Iris BioTechnologies (IRSB).
Who are TransEnterix's key executives?
TransEnterix's management team includes the folowing people:
- Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
- Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
- Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
- Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
- Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)
Who are TransEnterix's major shareholders?
TransEnterix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.02%), Vanguard Group Inc. (3.91%), Vanguard Group Inc (3.91%), Mirae Asset Global Investments Co. Ltd. (2.49%), Aisling Capital LLC (0.00%) and Artemis Investment Management LLP (0.61%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, SPA Sofar, Todd Pope, Willam N Kelley and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.
Which institutional investors are selling TransEnterix stock?
TRXC stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC, Eagle Asset Management Inc., AQR Capital Management LLC, SG Americas Securities LLC, Artemis Investment Management LLP, EAM Global Investors LLC, EAM Investors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold TransEnterix company stock in the last year include Anthony C J Fernando, Joseph P Slattery, Todd Pope and William N Starling Jr. View Insider Buying and Selling for TransEnterix.
Which institutional investors are buying TransEnterix stock?
TRXC stock was purchased by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., BlackRock Inc., Vanguard Group Inc, Vanguard Group Inc., Credit Suisse AG, AlpInvest Partners B.V., Morgan Stanley and Ontario Teachers Pension Plan Board. Company insiders that have bought TransEnterix stock in the last two years include Richard C Pfenniger Jr, SPA Sofar and Willam N Kelley. View Insider Buying and Selling for TransEnterix.
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $2.90.
What is TransEnterix's official website?
How can I contact TransEnterix?
TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
